Genitourinary Cancers | Specialty

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research.

Dr. Alva on TKI Monotherapy and Combinations for RCC

January 22nd 2020

Ajjai Shivaram Alva, MBBS, discusses TKI monotherapy and in combination with immunotherapy for patients with renal cell carcinoma.

FDA Approvals Boost Competition in Treatment Landscapes

January 18th 2020

Therapeutic developments in cancer were rewarded with a wave of approvals in 2019.

Dr. Bochner on Standardizing Molecular Profiling in Bladder Cancer

January 11th 2020

Bernard H. Bochner, MD, FACS, discusses the potential standardization of molecular profiling in bladder cancer.

Immunotherapy Combos Emerge as Standard Frontline Treatment in Advanced RCC

January 10th 2020

David F. McDermott, MD, discusses developments in the frontline setting for the treatment of patients with advanced renal cell carcinoma.

PARP Inhibitors, Vaccines, and Combos Spark Excitement in mRCC

January 10th 2020

Sumanta Kumar Pal, MD, discusses novel strategies on the horizon in renal cell carcinoma.

Dr. Flaig on Immune Checkpoint Inhibitors in Advanced Bladder Cancer

January 10th 2020

Thomas W. Flaig, MD, discusses the utility of immune checkpoint inhibitors in advanced bladder cancer.

Expert Explains Clinical Developments With Cytoreductive Nephrectomy in mRCC

January 9th 2020

Ulka Vaishampayan, MD, discusses the historical management of patients with metastatic renal cell carcinoma and how advances with systemic therapy have impacted the sequencing of cytoreductive nephrectomy in the treatment paradigm.

Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma

January 9th 2020

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Dr. McDermott on the Use of PD-1 Inhibitor Combos in mRCC

January 8th 2020

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Single-Agent and Combo Approvals Lead to Personalized Approach in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, highlights ongoing advances made in the treatment of patients with metastatic renal cell carcinoma.

Dr. Alva on the Toxicity Profiles of TKIs in RCC

January 6th 2020

Ajjai Shivaram Alva, MBBS, discusses class-specific toxicities of TKIs in renal cell carcinoma.

Dr. Vaishampayan on the Role of Cytoreductive Nephrectomy in mRCC

January 3rd 2020

Ulka Vaishampayan, MD, professor of oncology at Wayne State University, and the chief of the Solid Tumor Program at Barbara Ann Karmanos Cancer Institute, discusses the current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Predictive Biomarkers Needed for Immunotherapy Combo Choice in Frontline RCC

January 2nd 2020

Ulka Vaishampayan, MD, discusses the role of frontline immunotherapy and patient selection in metastatic renal cell carcinoma. 

Assessing Long-Anticipated Treatment Advances in Metastatic Urothelial Cancer

January 2nd 2020

Nancy B. Davis, MD, discusses the excitement with targeted therapies as well as anticipated combination strategies under investigation in advanced urothelial cancer.

Experts Provide Insight on the Biggest Advances in Oncology in 2019

January 1st 2020

OncLive interviewed experts at the State of the Science Summits™ in December 2019 on what the biggest advances in oncology were in 2019.

Frontline Pembrolizumab/Axitinib Approved in Japan for Advanced RCC

December 21st 2019

Japan’s Pharmaceuticals and Medical Devices Agency has approved the combination of pembrolizumab and axitinib for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma.

FDA Grants Priority Review to UGN-101 for Urothelial Cancer

December 19th 2019

The FDA has granted a priority review designation to a new drug application for UGN-101 for the treatment of patients with low-grade, upper tract urothelial cancer.

FDA Approves Enfortumab Vedotin for Urothelial Cancer

December 19th 2019

The FDA has approved enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have received prior treatment with a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy.

Frontline Immunotherapy Approvals Raise Treatment Selection Challenge in RCC

December 16th 2019

Robert J. Motzer, MD, discusses the current frontline treatment landscape of metastatic renal cell carcinoma amongst an influx of approvals.

Dr. Voss on Phase I/II Trial Data of MEDI0680/Durvalumab Versus Nivolumab in mRCC

December 6th 2019

Martin H. Voss, MD, discusses results of a randomized phase I/II trial looking at the combination of MEDI0680 and durvalumab (Imfinzi) versus nivolumab (Opdivo) in metastatic renal cell carcinoma.